Soligenix advances COVID-19 vaccine

By The Science Advisory Board staff writers

July 28, 2020 -- Biopharmaceutical firm Soligenix said that preclinical immunogenicity studies of its CiVax heat stable subunit COVID-19 vaccine candidate demonstrated that both broad-spectrum antibody immunity and cell-mediated rapid onset immunity are possible using the CoVaccine HT adjuvant.

Authored by collaborators from the University of Hawaiʻi at Mānoa, the article has been submitted to npj Vaccines for peer review. A manuscript preprint is available at

Moderna begins phase III testing of COVID-19 vaccine
Moderna has begun a phase III clinical trial evaluating its messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The trial is expected to enroll approximately...
Amyris partners with IDRI on scalable vaccine platform
Amyris and the Infectious Disease Research Institute (IDRI) have inked a binding term sheet for the development of a planned COVID-19 RNA vaccine technology...
Novavax, Fujifilm begin large-scale manufacturing of COVID-19 vaccine
Novavax and Fujifilm Diosynth have signed an agreement covering the bulk manufacture of Novavax's COVID-19 vaccine candidate, NVX-CoV2373, at Fujifilm's...
Cel-Sci reports positive early results with COVID-19 LEAPS conjugate
Cel-Sci completed animal testing using its Ligand Epitope Antigen Presentation System (LEAPS) COVID-19 conjugate, which means the firm can now move into...
Addressing the COVID-19 challenge with computer modeling & simulation
Each day, we wake up hoping for positive news about vaccines and therapies to combat COVID-19. More than 70 candidate molecules are being evaluated for...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter